Evaluation of Polysaccharide Typhim Vi Antibody Response as a predictor of Humoral Immunodeficiency in Haematological Malignancies

An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab respon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical immunology (Orlando, Fla.) Fla.), 2020-01, Vol.210, p.108307-108307, Article 108307
Hauptverfasser:	Ochoa-Grullón, J., Benavente Cuesta, C., Pérez López, C., Peña Cortijo, A., Rodríguez de la Peña, A., Álvarez Carmona, A., Mateo Morales, M., Llano-Hernández, K., Williams, L.J., Rodríguez de Frías, E., Guevara-Hoyer, K., Cordero Torres, G., Orte, C., Fernández-Arquero, M., Fernández-Paredes, L., Serrano-García, I., Recio, M.J., Pérez de Diego, R., Martínez, R., Sánchez-Ramón, S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Haematological malignancies Hypogammaglobulinemia Pneumo23 Specific polysaccharide ab response Typhim vi
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An increasing healthcare challenge in the management of haematological malignancy (HM) is secondary immunodeficiency. From January 2019, the EMA included the evaluation of specific antibody (Ab) responses to better select patients for immunoglobulin replacement therapy (IgRT). We evaluated Ab responses to pneumococcal and Salmonella typhi pure polysaccharide immunization in a cohort of 42 HM patients and 24 healthy-controls. Pre-post specific Ab concentrations were measured by ELISA at 4 weeks. Globally, significantly lower Typhim Vi (TV) seroprevalence (9%) compared to 23-valent pneumococcal polysaccharide vaccine (PPV) (76%) (p
ISSN:	1521-6616 1521-7035
DOI:	10.1016/j.clim.2019.108307